Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations
Authors:
- Johan GabrielssonJGJohan Gabrielsson
- Hugues DolgosHDHugues Dolgos
- Per-Göran GillbergPGPer-Göran Gillberg
- Ulf BredbergUBUlf Bredberg
- Bert BenthemBBBert Benthem
- Göran DukerGDGöran Duker
- 1 April 2009
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (7-8) , 358-372
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Drug–target residence time and its implications for lead optimizationNature Reviews Drug Discovery, 2006
- Target-based drug discovery: is something wrong?Drug Discovery Today, 2005
- Functional pharmacology: the drug discovery bottleneck?Drug Discovery Today: TARGETS, 2004
- Changes in plasma protein binding have little clinical relevanceClinical Pharmacology & Therapeutics, 2002
- The fall and rise of in vivo pharmacologyTrends in Pharmacological Sciences, 2002
- Predicting Effective Drug Concentrations for Individual PatientsClinical Pharmacokinetics, 1998
- Mechanism-based pharmacodynamic modelingClinical Pharmacology & Therapeutics, 1994
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarineClinical Pharmacology & Therapeutics, 1979
- Kinetics of pharmacologic effects in man: The anticoagulant action of warfarinClinical Pharmacology & Therapeutics, 1969